Estadisticas : Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Martin, M.
Visitas:1172

734 ( Estados Unidos de América )

159 ( Singapur )

85 ( Reino Unido )

44 ( Alemania )

44 ( Hong kong )

16 ( Letonia )

14 ( Irlanda )

13 ( Brasil )

9 ( España )

7 ( Finlandia )

6 ( Francia )

5 ( India )

3 ( China )

3 ( Canadá )

3 ( Vietnam )

3 ( Austria )

2 ( Togo )

2 ( Suiza )

2 ( Armenia )

2 ( Argentina )

1 ( Bangladesh )

1 ( Bélgica )

1 ( Jordania )

1 ( Países Bajos )

1 ( Taiwán )

1 ( Rumanía )

1 ( Bolivia )

1 ( Venezuela )

1 ( Egipto )

1 ( Irán )

1 ( Sudáfrica )

1 ( Indonesia )

1 ( Montenegro )

1 ( Uzbekistán )

1 ( Seychelles )

1 ( Arabia Saudita )

Descargas: 509